LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop†period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The "window shop†period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was receive. ...

Key Points Medtronic's growth has stalled in recent years. The company is bringing new products to market. Medtronic is also zeroing in on its most profitable businesses. 10 stocks we like better than Medtronic › Medtronic (NYSE: MDT) is out of favor today, noting it has a historically high dividend yield of around 3%. The company is working on improving its business performance, however, and stronger results are likely on tap. That could make Medtronic one of the best healthcare stocks you can bu ...

公司评价 - 知名评论员Jim Cramer强烈批评公司表现 称其为"失望之王"并建议投资者转投竞争对手Abbott Labs [1] - Parnassus Investments在2025年第二季度已清仓公司股票 转投Linde公司 因担忧其资本配置决策和管理层变动 [2] 业务概况 - 公司业务涵盖医疗器械、制药和数字健康技术 产品包括静脉注射解决方案、输液系统、手术产品、呼吸设备和专业注射剂 [2] - 产品主要应用于医院、诊所和家庭护理场景 对医院预算变化较为敏感 [2] 投资观点 - 尽管公司具备防御性特征 但机构投资者认为人工智能股票具有更大上涨潜力和更低下跌风险 [2] - 有观点认为某些人工智能股票可能从特朗普时代的关税政策和回流趋势中获益 [2]

Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discuss strategic collaboration at upcoming Italian Society for Organ and Tissue Transplantation ("SITO") in Milan ANDOVER, Mass. ...

InspireMD, Inc. (NASDAQ:NSPR) is among the  best fundamentally strong penny stocks to buy right now. According to the latest filing with the SEC, Parkman Healthcare Partners LLC has increased its position in InspireMD, Inc. (NASDAQ:NSPR) by 37.1% during the first quarter. Following the purchase of 316,700 shares, the institutional investor now owns 1,171,416 shares of the company’s stock, which translates to an ownership of nearly 3.82%. Powered by a clear procedure-agnostic strategy, InspireMD, Inc. (NAS ...

The private credit landscape continues to evolve amid economic headwinds, underscored the sector’s adaptability, the researchers at PitchBook have noted.Private credit, once a niche alternative to traditional lending, has surged as a go-to financing mechanism for middle-market companies grappling with syndicated loan market disruptions.This overview from PitchBook draws on fresh deal flow, quantitative insights, and expert perspectives to illuminate how direct lenders are stepping in where banks falter, par ...

LOS ANGELES--(BUSINESS WIRE)---- $TNDM--TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm. ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Boston Scientific Corporation is one of them Boston Scientific Corporation (NYSE:BSX) is emerging as a top AI-powered biotech stock by embedding artificial intelligence into its medical device portfolio, particularly in cardiology. Its AI strategy focuses on integrating advanced algorithms directly into revenue-generating devices like the WATCHMAN and FARAPULSE pulsed field ablation system, enhancing clinical out ...

Butterfly Network, Inc. (NYSE:BFLY) is among the best fundamentally strong penny stocks to buy right now. In the first quarter, Acadian Asset Management LLC raised its position in Butterfly Network, Inc. (NYSE:BFLY) by a whopping 270.5%. Following the purchase of 1,167,055 shares, the institutional investor now owns 1,598,552 shares of the company’s stock. With an ownership of 0.65%, the firm’s investment is worth $3,642,000. During its latest earnings call, the management highlighted that the second quar ...

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...